drugset
drugset / Trial / NCT04612699

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

NCT04612699 ↗

Phase 2 Completed 123 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

Timeline

Start
2021-03-11
Primary completion
2022-08-15
Completion
2022-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 50 mg Oral
Subject Jaktinib Unknown 75 mg Oral
Subject Jaktinib Unknown 100 mg Oral

Indications

psoriasis